2197.HK HKSE
Clover Biopharmaceuticals, Ltd.
1W: -13.1%
1M: -12.2%
3M: +4.7%
YTD: -22.8%
1Y: +179.7%
3Y: +84.5%
HK$1.86 ($0.24)
+0.08 (+4.48%)
Weekly Expected Move ±8.9%
HK$1
HK$2
HK$2
HK$2
HK$2
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$3M
-91.1% ▼
Gross Profit
-$24M
+96.5% ▲
Operating Income
-$248M
+74.0% ▲
Net Income
-$200M
+77.9% ▲
EPS (Diluted)
$-0.16
+77.8% ▲
EBITDA
-$221M
+75.9% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $39M | $38M | $3M |
| YoY Growth | +0.0% | +0.0% | +0.0% | -2.1% | -91.1% |
| Cost of Revenue | $66M | $476M | $15M | $711M | $27M |
| Gross Profit | -$66M | -$476M | $24M | -$673M | -$24M |
| Gross Margin | — | — | 61.8% | -1751.6% | -698.5% |
| R&D Expenses | $1.8B | $1.5B | $650M | $183M | $155M |
| SG&A Expenses | $346M | $113M | $107M | $40M | $65M |
| Operating Expenses | $2.2B | $1.9B | $896M | $278M | $224M |
| Operating Income | -$2.2B | -$2.4B | -$2.6B | -$951M | -$248M |
| Operating Margin | — | — | -6563.8% | -2475.9% | -7256.4% |
| Interest Expense | $3M | $6M | $19M | $6M | $367K |
| Income Before Tax | -$6.0B | -$2.5B | -$139M | -$903M | -$200M |
| Tax Expense | $2M | -$229K | $0 | $0 | $0 |
| Net Income | -$6.0B | -$2.5B | -$139M | -$903M | -$200M |
| Net Margin | — | — | -352.9% | -2351.5% | -5851.4% |
| EPS (Diluted) | $-5.36 | $-2.22 | $-0.11 | $-0.72 | $-0.16 |
| EBITDA | -$2.2B | -$2.4B | -$45M | -$917M | -$221M |
| Shares Outstanding | 1.12B | 1.10B | 1.24B | 1.25B | 1.26B |